Computed Tomography trials for Lung cancer

All Computed Tomography trials · All Lung cancer trials

Phase breakdown

Recruiting trials studying Computed Tomography for Lung cancer

• A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer
  NCT05242965 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab
  NCT07619599 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
  NCT07293247 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 74 locations
• Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
  NCT06616584 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 386 locations
• An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer
  NCT05558904 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
  NCT06014827 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
  NCT05733000 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Cardiovascular Injury and Cardiac Fitness in Locally Advanced Non-Small Cell Lung Cancer Patients Receiving Model Based Personalized Chemoradiation
  NCT05010109 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer
  NCT06249282 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
  NCT06096844 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 324 locations
• Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
  NCT05642572 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 454 locations
• Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer
  NCT03422302 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer
  NCT06495125 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy
  NCT06731270 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer
  NCT07017829 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
  NCT04119024 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• Gilteritinib for the Treatment of ALK NSCLC
  NCT06225427 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
  NCT06518057 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
  NCT06498635 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 279 locations
• Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
  NCT07288034 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 13 locations
• Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
  NCT04949464 · Phase: Not applicable (e.g. observational or device study) · Ages: 45 Years to 80 Years · Sex: All (male and female) · 11 locations
• LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
  NCT06073431 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 225 locations
• Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
  NCT04181060 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 603 locations
• PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
  NCT04151940 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
  NCT05775939 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
  NCT05098210 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
  NCT05269381 · Phase: Phase 1, Phase 2 · Ages: 16 Years and older · Sex: All (male and female) · 2 locations
• Phase II Trial of Lung Chemoemobolization
  NCT05672108 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Predictive Biomarkers for Pneumonitis After Chemoradiotherapy and Immunotherapy in Patients With Non-small Cell Lung Cancer
  NCT04913311 · Phase: Not specified · Ages: No age limits stated · Sex: All (male and female) · 1 location
• Q702 for the Treatment of Patients With Hematologic Malignancies
  NCT06712810 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
  NCT07322341 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
  NCT07012031 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 9 locations
• Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
  NCT05501665 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study
  NCT05802186 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
  NCT06116682 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 248 locations
• Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
  NCT06031688 · Phase: Phase 2 · Ages: 18 Minutes and older · Sex: All (male and female) · 266 locations
• Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer
  NCT07423585 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
  NCT07323641 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
  NCT06500455 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 270 locations
• Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
  NCT04665739 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 29 locations
• Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
  NCT06500481 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 58 locations
• Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
  NCT05624996 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 477 locations
• Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
  NCT04402788 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 415 locations
• Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
  NCT04267848 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1151 locations
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
  NCT05198830 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 34 locations
• Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
  NCT06287775 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 43 locations
• Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial
  NCT07388524 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 63 locations
• Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
  NCT05235165 · Phase: Phase 3 · Ages: Up to 50 Years · Sex: All (male and female) · 233 locations
• Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT
  NCT06360627 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Understanding New Cachexia Subtypes Through Observational Epidemiological Research
  NCT07776353 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
  NCT06769126 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 148 locations
• Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
  NCT06616623 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many trials study Computed Tomography for Lung cancer?

52 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.